Co-CEO Sells Controlling Stake for $11.2M, Resigns Amidst Company Distress
INDP is trading near its 52-week low of $1.52 (9.9% above the low).
Summary
David E. Lazar, co-CEO and director, sold preferred stock convertible into 108.9 million common shares for $11.2 million, representing a significant ownership transfer, and resigned as co-CEO, signaling a major shift in leadership and control for the financially distressed company.
Key Events · Ownership and Investor Activity · INDP
-
Co-CEO Resignation
David E. Lazar resigned as co-Chief Executive Officer, though he will remain a member of the Board of Directors.
-
Major Stake Sale
Lazar sold preferred stock convertible into an aggregate of 108.9 million common shares for $11.2 million to new purchasers.
-
Significant Ownership Transfer
The transaction represents a substantial transfer of potential equity, with Lazar's post-sale ownership (of retained shares) estimated at approximately 1.82% of the fully diluted common stock.
-
Distressed Context
This event follows closely on the heels of the company's disclosure of a going concern warning and the halting of its lead clinical program.
Analysis · INDP · Life Sciences
This Schedule 13D/A details a critical ownership change for Indaptus Therapeutics, occurring just days after the company disclosed a going concern warning and halted its lead clinical program. David E. Lazar, who resigned as co-Chief Executive Officer but remains a director, sold preferred stock convertible into 108.9 million common shares for $11.2 million to new purchasers. This transaction, representing a substantial portion of the company's potential equity, indicates a significant restructuring of the company's ownership and leadership under duress. The sale of such a large stake by a key insider, coupled with his resignation as co-CEO, suggests a major shift in strategic direction or control, likely driven by the company's severe financial challenges. Investors should view this as a strong signal of instability and a potential change in the company's future trajectory.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INDP was trading at $1.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $1.52 to $21.84. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.